Fox Chase Cancer Center News

PHILADELPHIA (July 15, 2020) – Fox Chase Cancer Center announces the hiring of Brandon Bachert, MD, who will join the department of diagnostic imaging as a full time body imager. Bachert will be an assistant professor on the academic track.

PHILADELPHIA (July 14, 2020) – J. Nicholas Bodor, MD, PhD, MPH, will join the Department of Hematology/Oncology and serve in the Thoracic Oncology Program upon completion of the Fox Chase-Temple Hematology/Oncology Fellowship Program.

PHILADELPHIA (July 13, 2020) – Genome Profiling and Fox Chase Cancer Center will collaborate to identify a novel immune system epigenetic biomarker, dubbed EpiMarker, which if successful, will be used to help predict which lung cancer patients are likely to respond to a checkpoint inhibitor therapy known as anti-PD1 antibody. These agents are a potentially valuable tool for lung cancer treatment, but it remains very difficult for doctors to predict which patients are most likely to benefit from them.

PHILADELPHIA (July 1, 2020)—Researchers at Fox Chase Cancer Center were part of a national team that published a paper identifying best practices for facilities to protect vulnerable cancer patients during the COVID-19 pandemic.

PHILADELPHIA (July 1, 2020)—In a recent study, researchers at Fox Chase Cancer Center found that factors other than just age can be useful in determining courses of treatment for older patients with locally advanced rectal cancer.

PHILADELPHIA (June 29, 2020)—Researchers at Fox Chase Cancer Center recently conducted a study analyzing the impact of sun exposure and tanning patterns on gene mutations in patients with advanced melanoma. Those who experienced blistering sunburn had a higher number of gene mutations in their tumors compared to those who did not experience blistering sunburn.

PHILADELPHIA (June 25, 2020) – The Accreditation Council for Graduate Medical Education (ACGME) review committee stated that the program “demonstrated outstanding compliance with the ACGME’s Program Requirements and/or Institutional Requirements.” ACGME would not require a site visit for the next 10 years, the longest duration allowed by the ACGME.

PHILADELPHIA (June 25, 2020)—Survival rates for Black patients were worse than those for white patients being treated for head and neck cancer even when they had access to the same care. The researchers said the disparities could be explained by biological differences between the two groups.